Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compulsory screening for Italian newborns:

This article was originally published in Clinica

Executive Summary

Italy has introduced compulsory screening for hypothyroidism and phenylketonuria in newborns, according to a report in the August 14 issue of The Lancet. Blood tests will be carried out between the third and fifth day after birth and the samples will be forwarded to a regional screening centre within 48 hours. The centres, which are each expected to process at least 60,000 samples a year, will also offer counselling to parents who are symptom-free carriers of genetic defects. The initiative also includes early diagnosis of congenital malformations and experimental screening for cystic fibrosis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT079325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel